Incyte Shares Purchased by Vestcor Inc

Institutional investor increases stake in biopharmaceutical company

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Vestcor Inc, an institutional investor, increased its position in shares of Incyte Corporation (NASDAQ:INCY) by 1,439.3% in the 3rd quarter, according to a recent SEC filing. The investor now owns 116,846 shares of the biopharmaceutical company's stock, worth approximately $9.91 million.

Why it matters

This significant increase in Vestcor's stake in Incyte suggests the institutional investor sees strong potential in the biopharmaceutical company, which develops novel therapies in oncology and inflammation. Incyte's flagship product is the FDA-approved drug Jakafi, used to treat certain blood disorders.

The details

According to the SEC filing, Vestcor purchased an additional 109,255 shares of Incyte in the 3rd quarter, bringing its total ownership to 116,846 shares, or approximately 0.06% of the company. Incyte is a Wilmington, Delaware-based biopharmaceutical firm focused on developing small-molecule drugs and biologics that target critical signaling pathways in cancer, autoimmune disorders, and rare diseases.

  • Vestcor increased its Incyte stake in the 3rd quarter of 2026.

The players

Vestcor Inc

An institutional investor that increased its stake in Incyte Corporation by 1,439.3% in the 3rd quarter of 2026.

Incyte Corporation

A Wilmington, Delaware-based biopharmaceutical company that develops novel therapies in oncology and inflammation, with its flagship product being the FDA-approved drug Jakafi.

Got photos? Submit your photos here. ›

The takeaway

Vestcor's significant increase in its Incyte holdings suggests the institutional investor sees strong potential in the biopharmaceutical company's pipeline and approved products, underscoring Incyte's position as a leader in developing innovative therapies for difficult-to-treat conditions.